Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Precision Antibody
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : To characterize an internalizing monoclonal antibody, identify its target by mass spectrometry as PTGFRN and shows its efficacy as ADC in vitro and in vivo, for several cancer types including head and neck cancers and spindle cell carcinoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
July 06, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Precision Antibody
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
